E-ISSN 2602-3164
EJMI. 2022; 6(3): 326-331 | DOI: 10.14744/ejmi.2022.54998

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors

Nail Paksoy1, Ferhat Ferhatoglu2, Izzet Dogan2, Naziye Ak3, Metin Pehlivan4, Meltem Ekenel1, Mert Basaran1
1Department of Medical Oncology, İstanbul University Institute of Oncology, İstanbul, Türkiye, 2Department of Medical Oncology, İstanbul Başakşehir City Hospital, İstanbul, Türkiye, 3Department of Medical Oncology, Yozgat City Hospital, Türkiye, 4Department of Medical Oncology, Zonguldak Ataturk State Hospital, Türkiye

Objectives: Desmoid tumors (DTs) are rare benign neoplasms characterized by histologically monoclonal fibroblastic proliferation. Although current treatment guidelines recommend active surveillance as the initial approach, systemic therapy should be considered in rapidly progressive or symptomatic patients. In this study, we aimed to evaluate the efficacy of the kinase inhibitor, sorafenib, as a treatment for patients with progressive or symptomatic DTs. Methods: The clinical, pathological, and demographic data of a sample of patients treated for DTs with sorafenib were retrospectively evaluated. Results: Seventeen patients were included in the study. The ratio of female to male patients was 2.4, and the median age was 32 (range: 14-65). Four (23.5%) patients had Gardner syndrome. The rates of extra-abdominal and ıntraintraabdominal tumors were 64.7% and 35.3%, respectively. The median follow-up duration before sorafenib treatment began was 6 years. Before sorafenib, 15 patients had undergone surgical resection. All patients had received a median of two lines of systemic therapy, and four (23.5%) patients had received chemotherapy. The median sorafenib treatment duration was 23.4 months. The 1 and 2 year progression-free survival rates were 94.1% and 80.7%, respectively. Grade 3–4 toxicities were observed in six (35.2%) of the patients. Conclusion: Sorafenib was deemed an effective treatment for previously treated advanced DTs. Keywords: Aggressive fibromatosis, desmoid tumors, gardner syndome, sorafenib,TKİ

Cite This Article

Paksoy N, Ferhatoglu F, Dogan I, Ak N, Pehlivan M, Ekenel M, Basaran M. Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors. EJMI. 2022; 6(3): 326-331

Corresponding Author: Nail Paksoy

Full Text PDF PDF Download